QuantideX® qPCR PML-RARA Kit*
Request more information about the QuantideX qPCR PML-RARA Kit
Sensitive and Scalable Detection of 3 PML-RARA Primary Fusion Transcripts
Bcr1, bcr2, and bcr3 aberrant fusions of the PML-RARA gene are hallmarks of acute promyelocytic leukemia (APL), a distinct and aggressive and time sensitive subtype of acute myeloid leukemia (AML). Quantification of PML-RARA fusion transcripts of translocation t(15;17) assesses tumor burden in studies for molecular remission in APL and is essential to accurate genotypic characterization of leukemic subtype. The QuantideX® qPCR PML-RARA Kit* offers sensitive and scalable detection of 3 PML-RARA aberrant fusions in a single, multiplex RT-qPCR reaction, with results in 5 hours.
Multiplex design reduces complexity and hands-on time
Figure 1. Comparison of plate layout for an 8 sample run between the (a) Multiplex Asuragen assay, with samples run in singlicate, resulting in only 19 reactions; and (b) a singleplex competitor assay, with samples run in duplicate, resulting in 52 reactions.
Figure 2. QuantideX qPCR PML-RARA kit* workflow
Download the QuantideX qPCR PML-RARA Kit Brochure
Resources
Prototype RT-qPCR PML::RARA Reagents and a Commercial PML-RARA Kit Yield Highly Correlated Results
| Category | Description |
|---|---|
| Portfolio | QuantideX | Oncology Monitoring |
| Assay Coverage | Multiplexed design: target and reference genes detected in same well • Long isoform (bcr1) • Short isoform (bcr3) • 95% Variable isoforms (bcr2); excludes very rare fusions involving ZBTB16, NPM1, NUMA1, TBLXR1, STAT5B or PRKAR1A genes |
| Reference Gene | ABL1 |
| Kit Size | 60 reactions (similar to BCR-ABL; minimum batch size of 4 samples) |
| Sample Type | High quality, intact RNA (K₂EDTA) |
| Controls | Positive Controls: High Positive, Low Positive Negative Control: ABL1 positive, PML-RARA negative |
| Calibrators | Multiplexed calibrators (4) |
| Assay Sensitivity | 1:10⁴ (4-log reduction) |
| Platform | ABI 7500 Fast (Dx); post-launch expansion to QS5/7 Pro (Dx) w/BCR-ABL portfolio |
| Regulatory | RUO only |
Request a Quote
Interested in becoming an Early Access Site?
Enrollment for early access sites will begin in Spring 2024.
*For Research Use Only. Not for use in diagnostic procedures.
QuantideX® qPCR PML-RARA Kit*
Request more information about the QuantideX qPCR PML-RARA Kit
Sensitive and Scalable Detection of 3 PML-RARA Primary Fusion Transcripts
Bcr1, bcr2, and bcr3 aberrant fusions of the PML-RARA gene are hallmarks of acute promyelocytic leukemia (APL), a distinct and aggressive and time sensitive subtype of acute myeloid leukemia (AML). Quantification of PML-RARA fusion transcripts of translocation t(15;17) assesses tumor burden in studies for molecular remission in APL and is essential to accurate genotypic characterization of leukemic subtype. The QuantideX® qPCR PML-RARA Kit* offers sensitive and scalable detection of 3 PML-RARA aberrant fusions in a single, multiplex RT-qPCR reaction, with results in 5 hours.
Multiplex design reduces complexity and hands-on time
Figure 1. Comparison of plate layout for an 8 sample run between the (a) Multiplex Asuragen assay, with samples run in singlicate, resulting in only 19 reactions; and (b) a singleplex competitor assay, with samples run in duplicate, resulting in 52 reactions.
Figure 2. QuantideX qPCR PML-RARA kit* workflow